# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# NCT05538026

# Study name

Effectiveness of fecal microbiota transplantation as add-on therapy in mild-to-moderate ulcerative colitis

# Methods

RCT conducted in Ukraine

# Participants

# Inclusion criteria

- Ages 18–60 years
- Endoscopically and morphologically confirmed UC with Partial Mayo score 4–6, Mayo Endoscopic subscore ≥ 1, fecal calprotectin > 150 μg/g
- Treatment with mesalazine 3 g/day for last 4 weeks
- Negative stool culture for pathogenic bacteria (Shigella spp, Salmonella spp, Campylobacter spp, Yersinia spp) and toxin-producing Clostridioides difficile

# Exclusion criteria

- Pregnancy, planning pregnancy, or lactation
- Postponed operations on abdominal cavity
- Severe mental disorders, alcohol or drug abuse
- Use of systemic corticosteroids, biologic agents, and probiotics within 8 weeks before study
- Any condition or circumstance that would prevent/interfere with either completion of study or analysis of results, in the opinion of investigator

# Interventions

# Experimental arm

- FMT via colonoscopy to proximal colon

# Control arm

- Mesalazine 3 g (2 g orally + 1 g rectally) once daily

# Outcomes

# Primary outcomes

- Change in Partial Mayo score > 2 at 8 weeks
- Changes in fecal calprotectin at 8 weeks

# Secondary outcomes

- Change in microbiome profile at 4 weeks

# Starting date

1 September 2020

# Contact information

Nazarii Kobyliak, Associate Professor, Endocrinology Department, Bogomolets National Medical University

# Notes

# Pai 2019

# Study name

PediCRaFT: Pediatric Crohn's Disease Fecal Transplant Trial (PediCRaFT)

# Methods

RCT conducted in Canada

# Participants

# Inclusion criteria

- Children and adolescents ages 3–17 years

Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.